ATRA-hydroxyimino

Target: This ligand targets cellular retinoic acid-binding protein 2 (CRABP-II) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for cellular retinoic acid-binding protein 2 (CRABP-II). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings cellular retinoic acid-binding protein 2 (CRABP-II) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Design for Degradation: ATRA-hydroxyimino can be used as a small-molecule warhead or binding handle in PROTAC constructs to recruit an E3 ligase and drive ubiquitination of a chosen target protein. This enables systematic testing of ternary complex formation, degradation potency, and selectivity across related protein isoforms.

• E3 Ligase Recruitment Optimization: In targeted protein degradation workflows, ATRA-hydroxyimino–based ligands can be paired with different E3 ligase recruiters to tune engagement strength and degradation kinetics. Researchers can compare ligase-dependent ubiquitination efficiency and optimize linker length and attachment geometry to maximize productive ternary complex stability.

• Structure–Activity Relationship Mapping: ATRA-hydroxyimino supports PROTAC structure–activity relationship studies by enabling systematic variation of chemical features that influence target binding and degradation outcomes. By correlating binding affinity, cellular target engagement, and loss of protein abundance, investigators can identify modifications that enhance degradation without increasing off-target effects.

• Mechanistic Studies of Ubiquitination: The ligand can be incorporated into PROTACs to probe degradation mechanisms, including ubiquitin chain formation and dependence on the ubiquitin–proteasome pathway. Using time-course experiments and proteasome inhibition, researchers can distinguish between degradation-driven versus reversible inhibition phenotypes and refine mechanistic hypotheses.

ATRA-hydroxyimino is a retinoid receptor/CRABP ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of ATRA-hydroxyimino is characterized by phenol or alcohol functionality; aldehyde/oxime-compatible carbonyl functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.